Ergonovine API Manufacturers
compare suppliers & get competitive offers
To view suppliers for this material, you need to be logged in first.
This is because of international laws regarding narcotic materials. Furthermore, the contents of this page are only accessible if you are professionaly active in the pharmaceutical industry. In case you are, it is possible to register on our platform, and after your account is approved by our team you will be able to view suppliers and send your request.
Looking for Ergonovine API 60-79-7?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Ergonovine. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Ergonovine
- Synonyms:
- Ergobasine , Ergometrina , Ergometrine , Ergometrinum , Ergonovine , Ergotrate maleate
- Cas Number:
- 60-79-7
- DrugBank number:
- DB01253
- Unique Ingredient Identifier:
- WH41D8433D
About Ergonovine
It's time for some technical information for the ones who understand chemistry: An ergot alkaloid with uterine and vascular smooth muscle contractile properties.
More information such as the structure, indication or toxicity is available on Drugbank, click the ID above.
Ergonovine is a type of Uterotonics
Uterotonics are a subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that are widely used in the field of obstetrics and gynecology. These drugs are primarily employed to induce or enhance uterine contractions, thereby promoting labor and preventing postpartum hemorrhage.
Uterotonics exert their pharmacological effects by targeting specific receptors in the smooth muscle of the uterus. One of the most commonly used uterotonics is oxytocin, a hormone naturally produced by the body during childbirth. Synthetic forms of oxytocin, known as oxytocin analogs, are also utilized in medical settings to initiate or augment labor.
In addition to oxytocin, other uterotonics include ergot alkaloids, such as methylergonovine, and prostaglandin analogs, such as misoprostol. These drugs act through different mechanisms to stimulate uterine contractions.
The administration of uterotonics requires careful monitoring and precise dosing to avoid complications. While they are generally safe and effective, uterotonics can cause side effects, including nausea, vomiting, and uterine hyperstimulation. Therefore, medical professionals closely monitor patients receiving uterotonics to ensure optimal outcomes.
Overall, uterotonics play a vital role in obstetric care, facilitating safe and efficient labor and preventing excessive bleeding after childbirth. These pharmaceutical APIs have significantly contributed to improving maternal and neonatal health worldwide, making them indispensable tools in the field of obstetrics and gynecology.
Ergonovine (Uterotonics), classified under Genitourinary Agents
Genitourinary agents are a category of pharmaceutical active ingredients (APIs) that are specifically designed to target and treat disorders related to the genitourinary system. The genitourinary system encompasses the organs and structures involved in the production, storage, and elimination of urine, as well as the reproductive organs.
These APIs play a crucial role in the treatment of various genitourinary conditions, including urinary tract infections (UTIs), erectile dysfunction, urinary incontinence, benign prostatic hyperplasia (BPH), and other related disorders. They exert their therapeutic effects by interacting with specific receptors or enzymes in the genitourinary system, regulating physiological processes, and restoring normal function.
Some commonly used genitourinary agents include alpha-blockers, which relax the smooth muscles in the prostate and bladder neck, improving urine flow in patients with BPH. Additionally, phosphodiesterase type 5 inhibitors (PDE5 inhibitors) are widely prescribed for erectile dysfunction, as they enhance blood flow to the penile tissues, facilitating erection.
These APIs are typically formulated into various dosage forms, such as tablets, capsules, creams, gels, or injections, allowing for convenient administration to patients. The development and production of genitourinary agents involve stringent quality control measures and compliance with regulatory guidelines to ensure safety, efficacy, and consistent product performance.
In summary, genitourinary agents form a crucial category of pharmaceutical APIs used to treat a range of disorders affecting the genitourinary system. Their targeted mechanisms of action and diverse dosage forms make them valuable tools in improving genitourinary health and enhancing patients' quality of life.
